Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nice
• Treatments: Tirbanibulin

Criteria

Inclusion Criteria:

• Age > 18 years

• Histologically confirmed,

• primary, previously untreated,

• superficial basal cell carcinoma (sBCC) not arising on the face or scalp, ≤ 15 mm (large axis)

Exclusion Criteria:

• BCC of the face or scalp

• BCC of non-superficial subtype

• BCC with large axis > 15mm

• Relapsing BCC

• Allergy to treatment

• Treatment with cryotherapy, imiquimod, PDT, or radiotherapy in the BCC area during the 6 months prior to the screening visit